Literature DB >> 25002890

Concordance of the tuberculin skin test and T-SPOT(®).TB test results in kidney transplant candidates.

Roya Sherkat1, Majid Yaran2, Parisa Shoaie3, Mojgan Mortazavi4, Shahrzad Shahidi4, Hossein Hamidi4, Shiva Seirafian4, Shahram Taheri4, Ziba Farajzadegan3, Soodabeh Rostami3.   

Abstract

BACKGROUND: Detection of latent tuberculosis infection (LTBI) in transplant candidates is very important. The tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are standard immunologic tools for LTBI detection. The aim of this study was to compare the TST results and T-SPOT(®).TB test (a type of IGRAs) in kidney transplant candidates for the screening of LTBI and follow the patients with positive test for an activation of tuberculosis (TB) after transplantation and using anti-TB prophylaxis.
MATERIALS AND METHODS: This study was a prospective study and carried out in 44 renal transplant candidates from March 2010 to February 2011 in the teaching hospitals of Isfahan University of Medical Sciences, Iran. TST and T-SPOT(®).TB test were performed and their results evaluated. Patients with a positive skin test and/or T-SPOT(®).TB test were started on anti-TB prophylaxis and followed after transplantation for an activation of their LTBI for 1 year.
RESULTS: Overall, 8 (18.2%) patients were positive for TST and 6 (13.6%) patients for T-SPOT(®).TB test. The agreement between TST and T-SPOT(®).TB test was moderate (κ = 0.49, 95% confidence interval 0.145-0.839). The overall agreement between TST and T-SPOT(®).TB test was 86%. No relation was found between the underlying diseases and TST or T-SPOT(®).TB test positivity. Although isoniazid prophylaxis was used for patients with positive TST and/or T-SPOT(®).TB test, one patient had reactivation of TB.
CONCLUSION: In kidney transplant candidates both TST and T-SPOT(®).TB test were comparable for the diagnosis of LTBI with reasonable agreement between the tests. However, further studies are needed to determine the ability of T-SPOT(®).TB test to detect LTBI and to evaluate the need for prophylaxis in these patients.

Entities:  

Keywords:  Kidney transplant; T-SPOT®.TB test; latent tuberculosis; tuberculin skin test

Year:  2014        PMID: 25002890      PMCID: PMC4078377     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


  15 in total

Review 1.  Mycobacterium tuberculosis infection in recipients of solid organ transplants.

Authors:  Patricia Muñoz; Claudia Rodríguez; Emilio Bouza
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

2.  [Advances in the diagnosis of latent tuberculosis infection in patients receiving renal replacement therapy].

Authors:  M Arias Guillén; R Palomar; M Arias
Journal:  Nefrologia       Date:  2011       Impact factor: 2.033

Review 3.  Latent tuberculosis: what the host "sees"?

Authors:  Hannah P Gideon; JoAnne L Flynn
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

4.  Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy.

Authors:  Urban Sester; Heike Junker; Tobias Hodapp; Alexandra Schütz; Bernhard Thiele; Andreas Meyerhans; Hans Köhler; Martina Sester
Journal:  Nephrol Dial Transplant       Date:  2006-08-25       Impact factor: 5.992

5.  Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation.

Authors:  S-H Kim; S-O Lee; I-A Park; S J Park; S-H Choi; Y S Kim; J H Woo; S-K Park; J S Park; S C Kim; D J Han
Journal:  Transpl Infect Dis       Date:  2010-01-25       Impact factor: 2.228

6.  Comparing the tuberculin skin test and T-SPOT.TB blood test in children.

Authors:  Andrea T Cruz; Abby M Geltemeyer; Jeffrey R Starke; Jaime A Flores; Edward A Graviss; Kim C Smith
Journal:  Pediatrics       Date:  2010-12-06       Impact factor: 7.124

7.  Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients.

Authors:  F Piana; L R Codecasa; P Cavallerio; M Ferrarese; G B Migliori; L Barbarano; E Morra; D M Cirillo
Journal:  Eur Respir J       Date:  2006-03-15       Impact factor: 16.671

8.  Diagnosis of latent tuberculosis infection in candidates for kidney transplantation (comparison of two tests).

Authors:  Zahra Ahmadinejad; Farid Azmoudeh Ardalan; Sepideh Safy; Gordafarin Nikbakht
Journal:  Acta Med Iran       Date:  2012

9.  Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology.

Authors:  José María Aguado; Julián Torre-Cisneros; Jesús Fortún; Natividad Benito; Yolanda Meije; Antonio Doblas; Patricia Muñoz
Journal:  Clin Infect Dis       Date:  2009-05-01       Impact factor: 9.079

10.  Contribution of interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test.

Authors:  José M Ramos; Catalina Robledano; Mar Masiá; Sofia Belda; Sergio Padilla; Juan C Rodríguez; Félix Gutierrez
Journal:  BMC Infect Dis       Date:  2012-07-31       Impact factor: 3.090

View more
  2 in total

Review 1.  Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis.

Authors:  Peter Auguste; Alexander Tsertsvadze; Joshua Pink; Rachel Court; Noel McCarthy; Paul Sutcliffe; Aileen Clarke
Journal:  BMC Infect Dis       Date:  2017-03-09       Impact factor: 3.090

2.  Agreement between the results of tuberculin skin test and Interferon-Gamma Release Assays in renal transplant candidates.

Authors:  Shiva Samavat; Sam Alahyari; Ali Sangian; Malihe Nasiri; Mohsen Nafar; Ahmad Firoozan; Fariba Samadian; Nooshin Dalili; Fatemeh Poorrezagholi
Journal:  J Res Med Sci       Date:  2021-10-18       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.